Lifesci Capital Comments on Larimar Therapeutics, Inc.’s Q1 2023 Earnings (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) – Analysts at Lifesci Capital issued their Q1 2023 earnings per share estimates for shares of Larimar Therapeutics in a report released on Tuesday, March 14th. Lifesci Capital analyst P. Dolezal anticipates that the company will earn ($0.26) per share for the quarter. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.08) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q2 2023 earnings at ($0.27) EPS, Q3 2023 earnings at ($0.32) EPS, Q4 2023 earnings at ($0.33) EPS and FY2023 earnings at ($1.18) EPS.

A number of other brokerages also recently commented on LRMR. Guggenheim restated a “buy” rating and set a $12.00 price objective on shares of Larimar Therapeutics in a research note on Wednesday. Citigroup started coverage on Larimar Therapeutics in a research note on Tuesday, December 13th. They set a “neutral” rating and a $4.00 price objective for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Larimar Therapeutics Price Performance

Shares of LRMR opened at $5.38 on Friday. The company has a market cap of $95.28 million, a P/E ratio of -3.49 and a beta of 0.51. The stock has a fifty day moving average price of $5.46 and a 200 day moving average price of $4.12. Larimar Therapeutics has a 12 month low of $1.53 and a 12 month high of $6.85.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LRMR. Dimensional Fund Advisors LP grew its position in Larimar Therapeutics by 18.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 29,212 shares of the company’s stock valued at $93,000 after buying an additional 4,474 shares in the last quarter. Golden State Equity Partners raised its position in shares of Larimar Therapeutics by 21.6% during the 1st quarter. Golden State Equity Partners now owns 30,415 shares of the company’s stock worth $123,000 after buying an additional 5,400 shares in the last quarter. Morgan Stanley raised its position in shares of Larimar Therapeutics by 2.0% during the 4th quarter. Morgan Stanley now owns 540,837 shares of the company’s stock worth $2,234,000 after buying an additional 10,544 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Larimar Therapeutics by 836.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,822 shares of the company’s stock worth $38,000 after buying an additional 10,560 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Larimar Therapeutics during the 3rd quarter worth about $42,000.

About Larimar Therapeutics

(Get Rating)

Larimar Therapeutics, Inc Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich’s ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.